| Assessment Status | Rapid Review Complete |
| HTA ID | 23057 |
| Drug | Talquetamab |
| Brand | Talvey® |
| Indication | Talquetamab is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2023 |
| Rapid review completed | 10/11/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talquetamab compared with the current standard of care. |
